In meningiomas, genome-wide CNV profiling from off-target reads identified WHO-relevant alterations, including CDKN2A/B deletions and 1p/22q co-deletions, supporting molecular upgrading in 9/58 (16%) of histologically lower grade tumours. This evidence concerns the gene CDKN2A and meningioma.